Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

ClinicalTrials.gov ID: NCT03210337

Public ClinicalTrials.gov record NCT03210337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts

Study identification

NCT ID
NCT03210337
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Enrollment
157 participants

Conditions and interventions

Conditions

Interventions

  • A-101 Topical Solution Drug
  • A-101 Vehicle Solution Drug

Drug

Eligibility (public fields only)

Age range
8 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2017
Primary completion
Mar 15, 2018
Completion
Mar 15, 2018
Last update posted
Apr 30, 2019

2017 – 2018

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
Aclaris Investigational Site Scottsdale Arizona 85225
Aclaris Investigational Site Rogers Arkansas 72758
Aclaris Investigational Site San Diego California 92103
Aclaris Investigational Site San Diego California 92123
Aclaris Investigational Site Miami Florida 33137
Aclaris Investigational Site Newnan Georgia 30263
Aclaris Investigational Site Arlington Heights Illinois 60005
Aclaris Investigational Site Indianapolis Indiana 46256
Aclaris Investigational Site Plainfield Indiana 46168
Aclaris Investigational Site Warren Michigan 48088
Aclaris Investigational Site Fridley Minnesota 55432
Aclaris Investigational Site New York New York 10155
Aclaris Investigational Site Broomall Pennsylvania 19008
Aclaris Investigational Site Fort Washington Pennsylvania 19034
Aclaris Investigational Site Fountain Inn South Carolina 29644
Aclaris Investigational Site Austin Texas 78759
Aclaris Investigational Site San Antonio Texas 78213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03210337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2019 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03210337 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →